Premium
Dose Adjustment for Normal Eating (DAFNE) in routine clinical practice: who benefits?
Author(s) -
Keen A. J. A.,
Duncan E.,
McKillopSmith A.,
Evans N. D.,
Gold A. E.
Publication year - 2012
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2011.03479.x
Subject(s) - medicine
Diabet. Med. 29, 670–676 (2012) Abstract Aims To explore the effectiveness of Dose Adjustment for Normal Eating in routine clinical practice in the UK. Methods Participants were 124 adults with Type 1 diabetes who had completed a Dose Adjustment for Normal Eating course. Data were collected before the course and again 1 year later on a variety of biological, psychological and social measures. Results There were a range of significant benefits consistent with Dose Adjustment for Normal Eating aims, including: better control among those with baseline HbA 1c ≥ 81 mmol/mol (9.6%) ( z = −2.8, P = 0.004); reduced number of participants reporting severe hypoglycaemia (χ² = 4.27, P = 0.039); total eradication of diabetic ketoacidosis (χ² = 4.17, P = 0.041) and lower diabetes‐related distress ( z = −4.5, P < 0.001). The most deprived of the clinic population were significantly under‐represented (χ² = 17.8, P = 0.001) and the levels of clinical depression were unusually low. Conclusions These results indicate that Dose Adjustment for Normal Eating delivered in routine clinical practice is associated with a range of benefits and that certain clinical and psychosocial characteristics are associated with better outcomes.